A successful CDMO relationship requires more than manufacturing capacity. Pharmaceutical innovators increasingly look for partners capable of supporting the complete development lifecycle.
A typical program can progress through route scouting → process development → analytical development → scale-up → clinical supply → regulatory support → validation → commercial manufacturing. Shilpa Pharma describes its API CDMO capabilities as supporting projects from early-stage route scouting and process development through clinical manufacturing, scale-up and long-term commercial supply.
A strong CDMO partner should offer scientific expertise, manufacturing capacity, analytical capabilities, regulatory experience, technology-transfer expertise, quality systems, supply-chain reliability, intellectual-property protection and transparent project management.
Shilpa Pharma's published case study describes a clinical API program involving 3 × 1 kg initial supply, 25 kg GMP material after process optimization and a planned 200 kg commercial production stage. The project involved pyrophoric reagents, KSM stability challenges, impurity control and chiral purity requirements above 98% purity and 99% ee.
The value of a CDMO is demonstrated not merely by installed capacity but by its ability to solve complex development problems and translate laboratory chemistry into reproducible, compliant manufacturing.
